Cargando…

Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies

BACKGROUND: The European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS) is a validated value scale for solid tumour anticancer treatments. Form 1 of the ESMO-MCBS, used to grade therapies with curative intent including adjuvant therapies, has only been evaluated for a l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Paluch-Shimon, Shani, Cherny, Nathan I, de Vries, Elisabeth G E, Dafni, Urania, Piccart, Martine J, Latino, Nicola Jane, Cardoso, Fatima
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7476474/ https://www.ncbi.nlm.nih.gov/pubmed/32893189 http://dx.doi.org/10.1136/esmoopen-2020-000743

Ejemplares similares

Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules
por: Dafni, Urania, et al.
Publicado: (2017)

Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1
por: Knapen, Daan Geert, et al.
Publicado: (2020)

EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies
por: Kiesewetter, Barbara, et al.
Publicado: (2020)

PB2707: ESMO-MAGNITUDE OF CLINICAL BENEFIT SCALE FOR HAEMATOLOGICAL MALIGNANCIES (ESMO-MCBS:H) VERSION 1.0
por: Kiesewetter, Barbara, et al.
Publicado: (2023)

ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers
por: Cherny, N I, et al.
Publicado: (2016)

Evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for adjuvant radiotherapy in breast cancer
por: Sapir, E., et al.
Publicado: (2023)

Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) scoring
por: Gyawali, B., et al.
Publicado: (2021)

“The first ones now, will later be last”: understanding the importance of historical context when reading ESMO-MCBS scores
por: Cherny, N.I., et al.
Publicado: (2022)

Cost-effectiveness analysis of the use of immunotherapy in metastatic solid tumours in Austria by applying the ESMO-Magnitude of Clinical Benefit Scale (ESMO-MCBS) version 1.1
por: Pichler, M., et al.
Publicado: (2021)

ESMO-Magnitude of Clinical Benefit Scale (MCBS) group
por: Amaral, Teresa
Publicado: (2019)

Applying the ESMO-Magnitude of Clinical Benefit Scale in real life
por: Ciardiello, Fortunato, et al.
Publicado: (2016)

Indicators of integration at ESMO Designated Centres of Integrated Oncology and Palliative Care
por: Hui, David, et al.
Publicado: (2018)

Implementation of the ESMO-Magnitude of Clinical Benefit Scale: real world example from the 2022 Israeli National Reimbursement Process
por: Wolf, I., et al.
Publicado: (2022)

ESMO gave me a chance to help make a difference: a personal reflection on the occasion of receiving the 2015 ESMO Award
por: Cherny, Nathan I
Publicado: (2016)

Palliative care: needs of advanced breast cancer patients
por: Cherny, Nathan I, et al.
Publicado: (2018)

ESMO and WHO: 14 years of working in partnership on cancer control
por: Ullrich, Andreas, et al.
Publicado: (2016)

Prioritising systemic cancer therapies applying ESMO’s tools and other resources to assist in improving cancer care globally: the Kazakh experience
por: Latino, N.J., et al.
Publicado: (2022)

Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain
por: Roitberg, F., et al.
Publicado: (2023)

ESMO Designated Centres of Integrated Oncology and Palliative Care (ESMO DCs): education, research and programme development survey
por: Kreye, G., et al.
Publicado: (2022)

Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey
por: Banerjee, Susana, et al.
Publicado: (2018)

Are Quality of Randomized Clinical Trials and ESMO-Magnitude of Clinical Benefit Scale Two Sides of the Same Coin, to Grade Recommendations for Drug Approval?
por: Rodriguez, Adela, et al.
Publicado: (2021)

Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO)
por: Morgan, Gilberto, et al.
Publicado: (2016)

Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015
por: Rolfo, Christian, et al.
Publicado: (2016)

COVID-19 in patients with cancer: first report of the ESMO international, registry-based, cohort study (ESMO-CoCARE)
por: Castelo-Branco, L., et al.
Publicado: (2022)

Measuring Clinical Benefit of Treatments for Hematologic Malignancies: Critical First Steps Accomplished—What is Next?
por: Gribben, John G., et al.
Publicado: (2020)

Comparison of Long-term Survival Benefits in Trials of Immune Checkpoint Inhibitor vs Non–Immune Checkpoint Inhibitor Anticancer Agents Using ASCO Value Framework and ESMO Magnitude of Clinical Benefit Scale
por: Everest, Louis, et al.
Publicado: (2019)

11 ESMO 2021 breakthroughs: practicing oncologist’s perceptions on data presentation
por: van Halteren, H.K., et al.
Publicado: (2022)

ESMO International Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in countries outside of Europe
por: Cherny, N I, et al.
Publicado: (2017)

From ESMO 2022
por: Romero, Diana
Publicado: (2022)

Clinical benefit of systemic therapies for recurrent ovarian cancer—ESMO-MCBS scores
por: Broekman, K.E., et al.
Publicado: (2021)

The hard road to ranking the clinical benefit of antineoplastic agents: ESMO Award 2016 presentation
por: Sobrero, Alberto
Publicado: (2017)

From ESMO TAT 2021
por: Killock, David
Publicado: (2021)

From the ESMO Congress 2021
por: Sidaway, Peter
Publicado: (2021)

5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
por: Cardoso, F., et al.
Publicado: (2020)

The correlation between the costs and clinical benefits of PD-1/PD-L1 inhibitors in malignant tumors: An evaluation based on ASCO and ESMO frameworks
por: Lin, Shen, et al.
Publicado: (2023)

ESMO 2017—my personal highlights
por: Kiesewetter, Barbara, et al.
Publicado: (2018)

My personal highlights of ESMO 2016
por: Dediu, M., et al.
Publicado: (2017)

Pain workshop ESMO: Africa (response)
por: Grant, Liz, et al.
Publicado: (2020)

ESMO 2021—highlights in colorectal cancer
por: Weiss, Lukas
Publicado: (2022)

ESMO 2020: highlights in breast cancer
por: Bartsch, Rupert
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ucj9ac0f744bmmtkrrrqbe2n4g